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Simple Summary: Ongoing clinical trials are recently investigating the efficacy of second-line EGFR
inhibitors in initially RAS mutant metastatic colorectal cancer patients who convert to RAS wild-type
in plasma, as assessed by circulating tumor DNA (ctDNA) analysis. To this purpose, discriminating
between patients with a real clearance of RAS mutations in plasma (real wild-type) from those
who do not shed ctDNA is mandatory. The aim of the present study was to confirm the presence
of ctDNA in patients with RAS mutation clearance in plasma at different time points, using a
colon-cancer-specific five-gene methylation panel. The methylation test confirmed the presence of
ctDNA in most RAS wild-type samples at the time of disease progression, thus confirming that the
negative selection of RAS mutant clones during the clonal evolution of mutant RAS colorectal cancer
is not an infrequent event.
Abstract: The clearance of RAS mutations in plasma circulating tumor DNA (ctDNA) from originally
RAS-mutant metastatic colorectal cancer (mCRC) has been recently demonstrated. Clinical trials
investigating whether RAS mutant mCRC who “convert” to wild-type in plasma might benefit from
EGFR blockade are ongoing. Detection of tumor-specific DNA methylation alterations in ctDNA
has been suggested as a specific tool to confirm the tumoral origin of cell-free DNA. We monitored
RAS clearance in plasma from patients with RAS-mutant mCRC at baseline (pre-treatment) (T0);
after 4 months of first-line therapy (T1); at the time of first (T2) and second (T3) progression. A five-gene
methylation panel was used to confirm the presence of ctDNA in samples in which RAS mutation
clearance was detected. At T1, ctDNA analysis revealed wild-type RAS status in 83% of samples,
all not methylated, suggesting at this time point the lack of ctDNA shedding. At T2, ctDNA analysis
revealed wild-type RAS status in 83% of samples, of which 62.5% were found methylated. At T3,
50% of wild-type RAS samples were found methylated. Non-methylated samples were found in
patients with lung or brain metastases. This five-gene methylation test might be useful to confirm the
presence of ctDNA in RAS wild-type plasma samples.
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1. Introduction
The use of cell-free DNA (cfDNA) to monitor cancer clonal evolution allows scientists to rapidly
identify the occurrence of drug resistance to targeted therapies [1–3]. In wild-type (wt) RAS metastatic
colorectal cancer (mCRC), the emergence of RAS mutant clones under the selective pressure of
epidermal growth factor receptor (EGFR) inhibitors has been widely described, providing a molecular
rationale for liquid biopsy-based adaptive therapies [4]. More recently, the negative selection of RAS
mutant clones in circulating tumor DNA has been described to occur in some patients with primary
RAS mutant mCRC, suggesting for the first time an unpredicted negative selection of RAS mutant
clones during the clonal evolution of this cancer type [5]. This observation led to the design of the
first clinical trials aimed to investigate the efficacy and safety of second-line EGFR inhibitors plus
chemotherapy in initially RAS mutant mCRC patients who convert to RAS wt in plasma at the time of
first disease progression (PD) [6,7]. However, it is mandatory to discriminate between patients with
an actual clearance of RAS mutations in plasma from those who are negative due to lack in cfDNA
of tumor origin. Detection of tumor-specific DNA methylation alterations in circulating tumor DNA
(ctDNA) has been suggested as a specific tool to confirm the presence of DNA of tumor origin in
plasma [8]. Circulating methylated DNA (cmDNA) defined by a five-gene panel was previously used
as a non-invasive treatment-monitoring assay and was associated with outcomes in mCRC patients [9].
The aim of the present study was to monitor the dynamics of RAS mutation clearance in plasma from
patients with RAS mutant mCRC early after starting first-line therapy and at the time of progression
from first- and second-line treatments. In parallel, a five-gene methylation panel was used to confirm
the presence of ctDNA in all plasma samples in which RAS mutation clearance was detected.
2. Results
Twelve patients with RAS mutant mCRC were enrolled, all with evidence of hepatic metastases
at the time of diagnosis. The median age was 64.8 (range 47–78). All patients were scheduled to
receive first-line therapy. Response to treatment was based on imaging documentation, mostly CT
scans, and coded according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
Molecular analysis of primary tumor tissues revealed the following RAS mutations: KRAS G12D
(two cases); KRAS G12V (three cases); KRAS G12C (three cases); KRAS G13D (one case); NRAS G12D
(one case); NRAS A146T (one case); NRAS Q61R (one case). All formalin-fixed and paraffin-embedded
(FFPE) tissue samples were classified as BRAF wt. Characteristics of patient population are shown
in Table 1. ctDNA samples were analyzed for specific KRAS and NRAS variants with real-time PCR
assays. All plasma samples in which mutant RAS could not be detected at any time points were
analyzed for colon-cancer-specific methylation signature, in order to establish the presence of DNA of
tumor origin in the circulation (Figure 1). Indeed, the lack of tumor-derived DNA in blood could yield
a false negative result in the RAS mutation test and confound the interpretation of RAS clearance.
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Table 1. Clinicopathologic characteristics of patients.
Patient Age Gender Primary Location Tissue RAS Status 1st Line Therapy Metastatic Site at 1st PD 2nd Line Therapy Metastatic Site at 2nd PD
1 68 M Right KRAS G12D Folfoxiri/Bev Lung/Peritoneum TAS-102 N.A. †
2 66 M Left KRAS G12V Folfiri/Bev Liver/Nodes Folfox/Bev Liver/Lung
3 76 F Rectum KRAS G12V Folfox/Bev Liver/Nodes Folfiri/Bev Liver/Lung
4 58 F Right KRAS G12C Folfoxiri/Bev Lung TAS-102 Brain
5 65 F Right NRAS G12D Folfiri/Bev Liver Folfox/Bev N.A. †
6 78 M Left KRAS G13D Folfiri/Bev Liver */Lung Folfox/Bev N.A. †
7 62 F Rectum KRAS G12V Folfox/Bev Liver/Lung Folfiri/Bev Liver/Lung
8 47 M Rectum NRAS A146T Folfoxiri/Bev Lung Folfiri/Aflibercept Liver/Lung
9 76 M Left NRAS Q61R Folfoxiri/Bev Liver/Nodes Folfiri/Aflibercept Lung
10 58 M Right KRAS G12C Folfox/Bev Liver/Lung Folfiri/Bev Lung
11 64 M Left KRAS G12C Folfiri/Bev Liver/Lung Folfiri/Aflibercept Lung/Peritoneum
12 60 F Right KRAS G12D Folfox/Bev Brain/Lung Folfiri/Bev Brain/Lung
* RAS wild-type status confirmed in metastatic tissue. Bev: bevacizumab F: female; M: male; N.A.: not available; PD: progressive disease; †: deceased.
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progressive disease (PD) (T2), and at the time of second PD (T3). 
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ancer p tients at b s line (T0), after 4 months of first-line therapy (T1), at the time of first progressive
disease (PD) (T2), and at the time of second PD (T3).
2.1. Plasma ctDNA Analysis at T0
The first plasma ctDNA analysis was performed at baseline (T0), before starting the first-line
therapy. Concordance in RAS mutational status between tissue and plasma samples was found for all
cases at T0. All plasma samples analyzed at baseline were found methylated.
2.2. Plasma ctDNA Analysis at T1
The second plasma sample was collected four months after starting first-line treatment (T1).
At that time, ten patients had a partial response (PR) and two had stable disease (SD). ctDNA analysis
revealed wt RAS status in 10/12 (83%) patients, while 2/12 (17%) were found RAS mutant, retaining the
same mutation as in T0. Methylation analysis of plasma-derived cfDNA (which was available in
eight out of the ten plasma samples with wt RAS status at T1) gave negative results in all the samples
analyzed, suggesting the lack of ctDNA shedding.
2.3. Plasma ctDNA Analysis at First-Line PD (T2)
The third plasma sample was collected at the time of PD from first-line treatment (T2). ctDNA
analysis revealed wt RAS status in 10/12 (83%) patients, while 2/12 (17%) were found RAS mutant,
one retaining the same mutation as in T0 and T1 and the other one reacquiring the same mutation as in
T0, although it found wt RAS at T1. Eight out of the ten wt RAS plasma samples were available for
methylation assay. Among the available samples, 5/8 (62.5%) were found methylated, while 3/8 (37.5%)
were not. Non-methylated samples were from patients with lung, peritoneum, or brain metastases at
the time of PD. In the only patient for whom a tissue biopsy of metastatic site was available (pt. 6),
wt RAS was confirmed, in agreement with the results obtained from plasma at the same time point.
2.4. Plasma ctDNA Analysis at Second-Line PD (T3)
The fourth plasma sample was available in nine patients at the time of PD from second-line
treatment (T3). ctDNA analysis revealed wt RAS status in 6/9 (67%) patients, while 3/9 (33%) were
found RAS mutant, with two individuals retaining the same mutation as in T2 and one acquiring a
new RAS mutation, different from the one detected at T0. Four out of the six wt RAS plasma samples
were available for methylation assay. Among the available samples, 2/4 (50%) were found methylated,
while 2/4 (50%) were not. Non-methylated samples were from patients with lung or brain metastases
at the time of second-line PD.
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3. Discussion
According to international guidelines, anti-EGFR therapy is not appropriate for patients with
RAS mutant mCRC [10]. In this group of patients, only anti-angiogenic drugs are available as targeted
therapy options. Our group has reported for the first time, in RAS mutant mCRC, an unexpected
negative selection of RAS mutant clones upon treatment with standard care therapy [6,7]. This indicates
that tumor cell population at relapse might be mainly composed of wt RAS clones, possibly opening a
therapeutic window with anti-EGFR in patients who “switch” to RAS wt status in plasma at the time
of disease progression. We and others recently reported that some RAS mutant mCRC patients who
convert to RAS wt status in blood might benefit from EGFR blockade. These preliminary observations
lead to the design of the KAIROS trial (eudract n. 2019-001328-36) aimed to evaluate the clinical impact
of these findings [11]. Despite the initial skepticism, the clearance of RAS mutation in plasma from
RAS mutant mCRC patients has now become a hot topic. To date, different groups are investigating
the impact of EGFR inhibitors in patients with RAS mutant tumors at diagnosis who convert to RAS
wt disease in blood during therapy [11–14]. Remarkably, the lack of RAS mutation detection in plasma
might also be ascribed to the insufficient amount of ctDNA in the sample. Thus, especially when using
a low sensitive ctDNA assay, it is necessary to know how to correctly interpret the wt RAS status as a
real switch or, alternatively, as the consequence of lack of ctDNA shedding. Noteworthy, the Idylla
ctKRAS Mutation Test is a qPCR assay that has an analytical sensitivity of ≤1% for KRAS mutations in
exons 2 and 3 and ≤5% for mutations in exon 4. Compared to ddPCR, Idylla ctKRAS assay might have
a reduced accuracy in RAS mutation detection below 1% mutant allele fraction (MAF). In this case,
a confirmatory test assessing the presence of ctDNA is necessary.
Some studies have provided evidence that RAS mutations at diagnosis might convert into RAS
wt status early in the course of therapies, thus leading to the hypothesis that RAS mutational load
reduction might be a surrogate for therapeutic response [15]. Conversely, Klein-Scory et al. recently
described RAS conversion in ctDNA early after the first-cycle of chemotherapy, with the maintenance
of RAS wt status at the time of progression, assuming that the tumor remained RAS wt through
the course of the disease [13]. Authors confirmed the shedding of ctDNA in the course of therapy
using a specific methylation test, specifically the presence of methylated WIF1-promoter fragments.
Nevertheless, WIF1 methylation test is not tumor specific, being WIF1 methylated in normal colon
mucosa as well, suggesting that the use of a broader panel of methylated loci would be more compliant
to liquid biopsy analyses to improve the positivity of ctDNA detection [8]. We here sought to monitor
RAS wt conversion in ctDNA confirming the presence of ctDNA through a broad five-gene methylation
panel. This methylation assay, which has a sensitivity of 0.09% [8] gave positive results in all the
plasma baseline samples analyzed. The methylation test was instead found negative in all plasma
samples collected after 4 months of first line therapy (6–8 cycles), suggesting that at this time point
the RAS wt status was likely to be ascribed to the absence of ctDNA or that RAS mutations were
present at level below the limit of detection. This is consistent with the partial response or stability of
disease obtained in all patients at that time point. Conversely, at the time of progression from first- and
second-line treatments, 62 and 50% of wt RAS plasma samples were found methylated, respectively,
suggesting that the wt RAS status in plasma might reflect a wt RAS disease. Of note, only patients with
metastatic spread to the peritoneum, lung or brain at T2 and T3 were found negative for methylation
test, confirming a tendency of these peculiar metastatic sites to release lower levels of ctDNA [16–18].
Although we only analyzed a small patient population, we found a switch to wt RAS disease in a high
percentage of patients at the time of disease progression. The main limit of this study is the lack of
information concerning RAS status in metastatic site at the time of progressive disease, due to the
difficulty to routinely perform biopsies from metastatic sites.
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4. Materials and Methods
Twelve therapy naïve patients with a primary RAS mutant mCRC at diagnosis (based on tissue
mutational analysis) were enrolled prior to first line therapy initiation. FFPE tissue sections from primary
tumors were examined by next-generation sequencing according to standard procedures. Blood samples
for ctDNA analysis were collected at the following four defined time-points: (1) pretreatment (before
starting first-line therapy, T0); (2) after 4 months of first-line therapy (6–8 cycles) (T1); (3) at the time
of first PD (T2); (4) at the time of second PD (T3). Blood draws were performed after obtaining
informed consent. Authorization to perform liquid biopsies was released by the Regional Ethical
Committee (No.:179/16), and the study was conducted in accordance with the Declaration of Helsinki.
Plasma samples were obtained by centrifugation of 6 mL of blood at 1500 rpm for 10 min, followed by
removal of plasma, which was further centrifuged at 13,000 rpm for 1 min. Plasma samples were
stored at −80 ◦C until Idylla™ (Biocartis) was used to analyze KRAS, NRAS and BRAF mutational
status in plasma samples. For methylation analysis, ctDNA was extracted from 1 mL of plasma for
each patient using Maxwell RSC system (Promega) according to the manufacturer’s instructions.
ctDNA (20 microliters) were subjected to bisulfite conversion using the EZ DNA methylation Gold
kit (Zymo Research), with final elution in 40 µl. Bisulfite converted ctDNA was assessed for the
methylation status of five genes (EYA4, GRIA4, ITGA4, MAP3K14-AS1, MSC), previously described
to be hypermethylated in CRC [9]. The positivity of methylation markers was defined as previously
described [9]. All PCR experiments were performed in duplicate in two technical replicates.
5. Conclusions
Recent literature shows that some RAS mutant mCRC switch to wt RAS disease in plasma,
and three clinical trials aimed to investigate whether these patients might benefit from EGFR inhibitors
are currently ongoing [7,12,16]. In order to avoid false negative results due to the low analytic sensitivity
of some liquid biopsy assays, confirming the presence of ctDNA in all wt RAS plasma samples is
mandatory [19,20]. We here suggest that the use of a tumor specific, five-gene methylation panel might
be helpful to discriminate cases with a real negative clonal selection of RAS mutant clones from those
characterized by a lack of ctDNA shedding.
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